Immunic highlights MS treatment progression at BIO International Convention in Boston

Proactive - Interviews for investors

Immunic Inc (NASDAQ:IMUX) president and chief operating officer Jason Tardio joined Proactive's Stephen Gunnion from the BIO International Convention in Boston with more on recent clinical developments. Tardio highlighted Immunic’s ongoing business development efforts, particularly around its lead asset, vidofludimus calcium, aimed at treating multiple sclerosis (MS). Tardio described the compound as the first dual-mechanism treatment in development for MS, addressing both neuroinflammation and neurodegeneration. He explained, “Vidofludimus calcium is a highly selective DHODH inhibitor and also the first medicine in development that's an activator of Nurr1, which we know will provide neuroprotective benefits.” The recent Phase 2 CALLIPER trial in progressive MS involved 467 patients and showed a 24% reduction in confirmed disability worsening versus placebo. Subgroup analysis showed up to a 35% reduction in disability in primary progressive MS patients without inflammatory disease activity—a group previously lacking effective treatment options. Tardio also discussed the company’s Phase 3 ENSURE trials in relapsing MS, which have now completed enrollment with over 1,100 patients each. Topline results are expected in the latter part of 2026. Beyond clinical developments, he commented on industry themes at the conference, including funding challenges and a shared focus on patient-driven innovation. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #Immunic #MultipleSclerosis #MSResearch #BiotechNews #VidofludimusCalcium #ProgressiveMS #Neurodegeneration #BIO2025 #PharmaInnovation #ClinicalTrials